Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy - Implications for a pathologist

Breast Journal

Volumn 13, Issue 5, 2007, Pages 457-464

  Shet, Tanuja ^a,b   Agrawal, Atin ^a   Chinoy, Roshni ^a   Havaldar, Rohini ^a   Parmar, Vani ^a   Badwe, Rajan ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b NONE   (India)

Author keywords

Bcl2; Cerb2; Hormone receptors; Locally advanced breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; HORMONE RECEPTOR; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN CERB2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE; MAJOR CLINICAL STUDY; PATHOLOGIST; PROTEIN EXPRESSION;

ADULT; AGED; BREAST; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 34548271350     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2007.00465.x     Document Type: Article

References (31)

1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998 16 : 2672 85.
2. Sneige N, Kemp L, Pusztai L, Asmar L, Hortobagyi GN. Chemotherapy induced histologic changes in mastectomy specimens and their potential significance. Breast 2001 10 : 492 500.
3. Frierson HF, Fechner RE. Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy. Am J Clin Pathol 1994 102 : 154 57.
4. Kennedy S, Merino MJ, Swain SM, Lippman ME. The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. Hum Pathol 1990 21 : 192 98.
5. Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Am Surg 1996 62 : 162 65.
6. Wang J, Buchholz TA, Middleton LP, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 2002 94 : 3107 14.
7. El-Didi MH, Moneer MM, Khaled HM, Makarem S. Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management. Surg Today 2000 30 : 249 54.
8. Newman LA, Pernick NL, Adsay V, et al. Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol 2003 10 : 734 39.
9. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin based neoadjuvant chemotherapy. J Clin Oncol 1999 17 : 460 67.
10. Sharkey FE, Addington SL, Fowler LJ, Page CP, Cruz AB. Effects of preoperative chemotherapy on the morphology of respectable breast carcinoma. Mod Pathol 1996 9 : 893 900.
11. Costa MJ, Stewart G, Perez EA, Goodnight JE. Fine needle aspiration cytology in locally advanced breast carcinoma: a case with complete response to preoperative chemotherapy in association with granulomatous inflammatory reaction. Diagn Cytopathol 1994 10 : 357 61.
12. Kuerer HM, Newman LA, Buzdar AU, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 1998 4 : 230 36.
13. Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000 89 : 2187 94.
14. Anderson BO. Pathologic Response to Preoperative Systemic Therapy: The New Biological Paradigm for Predicting Outcome and Planning Therapy. Ann Surg Oncol 2003 10 : 713 15.
15. Quddus RM, Sung JC, Zhang C, Pasqueriello T, Eklund M, Steinhoff MM. HER-2/neu expression in Locally Advanced Breast Carcinomas: Pre-and Post-Neoadjuvant Chemotherapy. Breast Cancer 2005 12 : 294 98.
16. Sjostrom J. Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol 2002 41 : 334 45.
17. Amat S, Penault-Llorca F, Cure H, et al. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002 20 : 791 96.
18. Pinder SE, Murray S, Ellis IO, et al. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer 1998 83 : 1529 39.
19. Sjostrom J, Krajewski S, Franssila K, et al. A multivariate analysis of tumor biologic factors predicting response to cytotoxic treatment in advanced breast cancer. Br J Cancer 1998 78 : 812 15.
20. Aas T, Geisler S, Paulsen T, et al. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer: clinical experience and parameters predicting outcome. Acta Oncol 1996 35 (Suppl. 5 5 8.
21. Meric F, Mirza NQ, Buzdar AU, et al. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3 N0 M0 breast cancer. Ann Surg Oncol 2000 7 : 435 40.
22. Colleoni M, Minchella I, Mazzarol G, et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000 11 : 1057 59.
23. Chang J, Powles TJ, Allred DC, et al. Biologic makers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999 17 : 3058 63.
24. Aas T, Geisler S, Eide GE, et al. Predictive value of tumor cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2003 39 : 438 46.
25. Willsher PC, Pinder SE, Gee JM, et al. Cerb2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. Anticancer Res 1998 18 : 3695 98.
26. Muss HB, Thor AD, Berry DA, et al. cerbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994 330 : 1260 66.
27. Vincent-Salomon A, Carton M, Freneaux P, et al. ERBB2 over expression in breast carcinomas: no positive correlation with complete pathologic response to preoperative high dose anthracycline based chemotherapy. Eur J Cancer 2000 36 : 586 91.
28. Buchholz TA, Davis DW, McConkey DJ, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 2003 9 : 33 41.
29. Gasparini G, Barbareschi M, Doglioni C, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995 1 : 189 98.
30. Ellis PA, Smith IE, Detre S, et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998 48 : 107 16.
31. Bonetti A, Zaninelli M, Leone R, et al. Bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 1998 4 : 2331 36.